Responses
Extended reports
Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.